UA96592C2 - Індолопіридини як модулятори кінезину eg5 - Google Patents

Індолопіридини як модулятори кінезину eg5

Info

Publication number
UA96592C2
UA96592C2 UAA200811328A UAA200811328A UA96592C2 UA 96592 C2 UA96592 C2 UA 96592C2 UA A200811328 A UAA200811328 A UA A200811328A UA A200811328 A UAA200811328 A UA A200811328A UA 96592 C2 UA96592 C2 UA 96592C2
Authority
UA
Ukraine
Prior art keywords
indolopyridines
kinesin modulators
kinesin
modulators
compounds
Prior art date
Application number
UAA200811328A
Other languages
English (en)
Russian (ru)
Inventor
Маттіас Веннеманн
Томас Бер
Юрген Браунгер
Астрід Зіммерманн
Фолкер Гекелер
Original Assignee
4Сц Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Сц Аг filed Critical 4Сц Аг
Publication of UA96592C2 publication Critical patent/UA96592C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Винахід стосується сполуки формули І EMBED ISISServer , в якій R1, R2, R3, R4, R5 і R6 мають значення, вказані в описі винаходу; фармацевтичної композиції на її основі; а також застосування сполуки формули І для лікування (гіпер)проліферативних захворювань та/або станів чутливих до індукування апоптозу, наприклад доброякісна та/або злоякісна неоплазія та/або рак.
UAA200811328A 2006-02-22 2007-02-21 Індолопіридини як модулятори кінезину eg5 UA96592C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06110295 2006-02-22
EP06119038 2006-08-16
PCT/EP2007/051688 WO2007096393A1 (en) 2006-02-22 2007-02-21 Indolopyridines as eg5 kinesin modulators

Publications (1)

Publication Number Publication Date
UA96592C2 true UA96592C2 (uk) 2011-11-25

Family

ID=37964159

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200811328A UA96592C2 (uk) 2006-02-22 2007-02-21 Індолопіридини як модулятори кінезину eg5

Country Status (18)

Country Link
US (1) US8530493B2 (uk)
EP (3) EP1996592B1 (uk)
JP (1) JP5349056B2 (uk)
KR (1) KR101415354B1 (uk)
CN (1) CN101389628B (uk)
AR (1) AR059609A1 (uk)
AU (1) AU2007217560B2 (uk)
BR (1) BRPI0708233A2 (uk)
CA (1) CA2643488C (uk)
EA (1) EA015150B1 (uk)
HK (1) HK1205510A1 (uk)
IL (1) IL193625A (uk)
MX (1) MX2008010801A (uk)
NZ (1) NZ571357A (uk)
TW (1) TWI377207B (uk)
UA (1) UA96592C2 (uk)
WO (1) WO2007096393A1 (uk)
ZA (1) ZA200808070B (uk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
DE602005024572D1 (de) 2004-08-18 2010-12-16 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
SI1901729T1 (sl) * 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
EP2098524A1 (en) * 2008-03-05 2009-09-09 4Sc Ag Process for preparing enantiomerically pure indolopyrinidines
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN109467555A (zh) * 2018-06-21 2019-03-15 广东蓝堡生物科技有限公司 一种他达那非衍生物及其制备方法和应用
CN109160914B (zh) * 2018-11-17 2020-06-16 重庆文理学院 一种双吲哚并吡啶类衍生物的合成方法及在抗肿瘤中的应用
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途
CN113577063B (zh) * 2021-08-30 2022-08-16 广州领晟医疗科技有限公司 一种化合物在制备治疗炎性肠病的药物中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19744257B4 (de) 1997-10-07 2004-04-15 Zentaris Gmbh Beta-Carboline und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
AU2002213421A1 (en) 2000-10-03 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
WO2002095361A2 (en) 2001-05-22 2002-11-28 President And Fellows Of Harvard College Identification of anti-protozoal agents
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4580932B2 (ja) 2003-06-12 2010-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤のプロドラッグ
CN1960725A (zh) 2004-03-15 2007-05-09 Ptc医疗公司 用于抑制血管发生的四环咔啉衍生物
DE602005024572D1 (de) * 2004-08-18 2010-12-16 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
AU2006212863A1 (en) 2005-02-10 2006-08-17 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2007144384A1 (en) 2006-06-14 2007-12-21 4Sc Ag Pyrazolopyrimidones
WO2008006883A2 (en) 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles

Also Published As

Publication number Publication date
TW200815441A (en) 2008-04-01
EP1996592B1 (en) 2014-08-27
HK1205510A1 (en) 2015-12-18
EP2824105B1 (en) 2021-03-31
EA200801739A1 (ru) 2009-04-28
IL193625A0 (en) 2009-05-04
US20090233902A1 (en) 2009-09-17
IL193625A (en) 2015-01-29
CN101389628A (zh) 2009-03-18
CA2643488A1 (en) 2007-08-30
NZ571357A (en) 2010-11-26
AU2007217560A1 (en) 2007-08-30
AR059609A1 (es) 2008-04-16
BRPI0708233A2 (pt) 2011-05-24
KR101415354B1 (ko) 2014-07-04
MX2008010801A (es) 2008-09-05
CN101389628B (zh) 2013-02-27
US8530493B2 (en) 2013-09-10
EA015150B1 (ru) 2011-06-30
EP1996592A1 (en) 2008-12-03
CA2643488C (en) 2014-08-05
ZA200808070B (en) 2014-03-26
JP5349056B2 (ja) 2013-11-20
EP2824105A1 (en) 2015-01-14
KR20080098043A (ko) 2008-11-06
AU2007217560B2 (en) 2012-06-28
TWI377207B (en) 2012-11-21
JP2009527533A (ja) 2009-07-30
WO2007096393A1 (en) 2007-08-30
EP3862354A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
BRPI0906545A2 (pt) "aparelhos, sistemas e métodos de extensão da vida útil de meio de tratamento de alimento por inibição da degradação do mesmo"
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
TW200716624A (en) Compounds for modulating TRPV3 function
MX2009014247A (es) Compuestos heterociclicos utiles como inhibidores de mk2.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
PT2117521E (pt) Sistemas de administração transdérmica que compreendem bupivacaína
MX2009004766A (es) Derivados de espiroindolinona.
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
EA200801852A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA200802111A1 (ru) Имплантаты для лечения состояний, ассоциируемых с допамином
TNSN08496A1 (en) Aminothiazoles and their uses
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
WO2008006883A3 (en) Benzopyranopyrazoles
TW200738267A (en) Methods of increasing lymphatic function
WO2006125813A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006125815A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
DE502008001951D1 (de) Axomadol zur schmerzbehandlung bei arthrose
PH12014500538A1 (en) Methods and compositions for treating leukemia
ATE499138T1 (de) Implantierbare vorrichtung
EA200701626A1 (ru) Новые 6-пиридилфенантридины
IL173104A0 (en) Siva and ubiquintination